<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Coupon More | Hines Langhoff | Aktivität</title>
	<link>https://coupon-more.com/members/icerock9/activity/</link>
	<atom:link href="https://coupon-more.com/members/icerock9/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Aktivitäts-Feed für Hines Langhoff.</description>
	<lastBuildDate>Sun, 28 Jun 2026 08:58:30 +0200</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>de</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">49436c03e7e38239e8892d2a2578f4c0</guid>
				<title>Hines Langhoff postete ein Update: In this review, types of ocular barriers and drug [&#133;]</title>
				<link>https://coupon-more.com/activity/p/68432/</link>
				<pubDate>Wed, 25 Sep 2024 11:33:09 +0200</pubDate>

									<content:encoded><![CDATA[<p>In this review, types of ocular barriers and drug administration routes are categorised in a more intuitive way. Recent advances in nanocarrier mediated drug delivery systems with focus on posterior segment are reviewed with illustrative examples.Here we use the ALSUntangled methodology to review Tamoxifen as an ALS treatment. We show that it has&hellip;<span class="activity-read-more" id="activity-read-more-68432"><a href="https://coupon-more.com/activity/p/68432/" rel="nofollow ugc">[Weiterlesen]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">24b7be48de6b7232bbcebe57bba50b48</guid>
				<title>Hines Langhoff wurde ein Mitglied</title>
				<link>https://coupon-more.com/activity/p/62315/</link>
				<pubDate>Wed, 18 Sep 2024 08:09:44 +0200</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>